Wall Street sees huge upside as Novo Nordisk backs biotech company
Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough sell with Novo Nordisk (NVO) and Eli Lilly (LLY) already owning the narrative with blockbuster …
Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough sell with Novo Nordisk (NVO) and Eli Lilly (LLY) already owning the narrative with blockbuster …
Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough sell with Novo Nordisk (NVO) and Eli Lilly (LLY) already owning the narrative with blockbuster …
The full story continues on The Street.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.